SG11202109290YA - Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites - Google Patents

Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites

Info

Publication number
SG11202109290YA
SG11202109290YA SG11202109290YA SG11202109290YA SG11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA
Authority
SG
Singapore
Prior art keywords
serine189
rubicon
target sites
kinase inhibition
lrrk2 kinase
Prior art date
Application number
SG11202109290YA
Other languages
English (en)
Inventor
Lai Ling Sharon Chan
Eng King Tan
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11202109290YA publication Critical patent/SG11202109290YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202109290YA 2019-03-07 2020-03-06 Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites SG11202109290YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201902046S 2019-03-07
PCT/SG2020/050113 WO2020180257A1 (fr) 2019-03-07 2020-03-06 Thréonine166 et sérine189 d'un domaine rubicon run servant de sites cibles d'inhibition de la kinase lrrk2

Publications (1)

Publication Number Publication Date
SG11202109290YA true SG11202109290YA (en) 2021-09-29

Family

ID=72338780

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109290YA SG11202109290YA (en) 2019-03-07 2020-03-06 Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites

Country Status (5)

Country Link
US (1) US20220169720A1 (fr)
EP (1) EP3935082A4 (fr)
CN (1) CN113710700A (fr)
SG (1) SG11202109290YA (fr)
WO (1) WO2020180257A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3872170A1 (fr) * 2020-02-25 2021-09-01 University of Georgia Research Foundation, Inc. Modulateurs allostériques chimiquement stabilisés de répétition kinase 2 riche en lucine (lrrk2)
JP7486669B2 (ja) 2020-10-26 2024-05-17 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ エリカ キャンパス 結核、非結核抗酸菌感染疾患、及び潜在性結核診断用バイオマーカー及びその用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030936A2 (fr) * 2008-09-12 2010-03-18 Mount Sinai School Of Medicine Of New York University Atg14l et rubicon : nouveaux régulateurs de l'autophagie
US20110229905A1 (en) * 2008-12-04 2011-09-22 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases rlated to beclin-1
WO2014046966A1 (fr) * 2012-09-24 2014-03-27 Board Of Regents, The University Of Texas System Phosphorylation de la bécline 1
WO2020022499A1 (fr) * 2018-07-27 2020-01-30 国立大学法人大阪大学 Composition pour l'inhibition du vieillissement, la prévention, l'atténuation ou le traitement de maladies liées à l'âge, ou le prolongement de la durée de vie

Also Published As

Publication number Publication date
US20220169720A1 (en) 2022-06-02
EP3935082A1 (fr) 2022-01-12
CN113710700A (zh) 2021-11-26
WO2020180257A1 (fr) 2020-09-10
EP3935082A4 (fr) 2023-01-11

Similar Documents

Publication Publication Date Title
SG11202106635WA (en) Combination of antibody-drug conjugate and kinase inhibitor
IL282774A (en) Expansion of infiltrative lymphocytes (tils) using akt channel inhibitors
EP3573623A4 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
EP3806858A4 (fr) Sels d'inhibiteurs de kinases et compositions associées
EP3638229A4 (fr) Inhibiteurs de la kinase alk2 contenant de l'imidazole
FI3651768T3 (fi) Heterosyklisiä ATR-kinaasin inhibiittoreita
EP3768267A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3856164A4 (fr) Formes morphiques d'inhibiteurs du facteur d du complément
SG11202109290YA (en) Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites
SG11202008925VA (en) Inhibitors of micro-rna 22
EP3765008A4 (fr) Inhibiteurs hétérocycliques de la kinase atr
SG11202105881RA (en) Tyrosine kinase inhibitors, compositions and methods there of
EP3250192A4 (fr) Compositions et procédés d'utilisation d'inhibiteurs de tyrosine kinase
EP3402521A4 (fr) Inhibition de réaction allergique à l'aide d'un inhibiteur d'il-33
EP3906233A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3906028A4 (fr) Composés inhibiteurs de kinase, compositions et méthodes d'utilisation
IL279586A (en) Methods and preparations for the inhibition of dihydrourotate dehydrogenase
EP3661552A4 (fr) Compositions et méthodes d'inhibition de l'élimination de mica/b
IL288903A (en) Indazoles and azaindazoles as lrrk2 repressors
EP3768301A4 (fr) Compositions et méthodes d'inhibition de fas
GB2572259B (en) Uses of curcumin derivative
EP3990442C0 (fr) Inhibiteurs de la rho kinase et compositions et procédés d'utilisation de ceux-ci
EP3787655A4 (fr) Compositions et procédés se rapportant à un extrait de rhamnus prinoides (gesho) pour l'inhibition de la formation de biofilm polymicrobien
EP3717475A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3687514A4 (fr) Méthodes et compositions pour l'inhibition de stat3